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Abstract 
The accurate characterization of the molecular mechanisms involved in the action of receptor 
ligands is important for their appropriate therapeutic use and safety. 
It is well established that ligands acting at the histamine system currently used in the clinic exert 
their actions by specifically antagonizing G-protein coupled H1 and H2 receptors. However, most of 
these ligands, assumed to be neutral antagonists, behave as inverse agonists displaying negative 
efficacy in experimental systems. This suggests that their therapeutic actions may involve not only 
receptor blockade, but also the decrease of spontaneous receptor activity. 
The mechanisms whereby inverse agonists achieve negative efficacy are diverse. Theoretical 
models predict at least three possible mechanisms, all of which are supported by experimental 
observations. Depending on the mechanism of action engaged, the inverse agonist could interfere 
specifically with signaling events triggered by unrelated receptors. This possibility opens up new 
venues to explain the therapeutic actions of inverse agonists of the histamine receptor and perhaps 
new therapeutic applications.  
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1. Histamine receptors and its role in human health. 
Histamine is a biogenic amine synthesized from L-histidine by histidine decarboxylase. This amine 
plays an important role in human health and disease. It exerts its biologic effects acting through four 
receptor subtypes, termed H1, H2, H3, and H4. These receptors differ in their expression, molecular 
characteristics, resulting in differences in associated signal transduction pathways and function (Hill 
et al., 1997; Leurs et al., 2009). Nevertheless, all types of histamine receptors belong to the seven 
transmembrane spanning family of receptors, also known as GPCRs. 
 
The histamine H1 receptor is in fact the classical histamine receptor. This is one of many receptors 
that influence cellular homeostasis by modifying phospholipase C activity via interactions with 
Gproteins from the Gq/11 family. Following the original observations of Hokin and Hokin in 1953 
(Hokin and Hokin, 1953), histamine-induced incorporation of 32P in phosphatidylinositol was first 
reported in 1975 in the rat brain in vivo (Friedel and Schanberg, 1975). In a seminal study in the 
same system, ligand binding with specific H1 receptor ligands paralleled the development of 
histamine-induced incorporation of 32P into phosphoinositides, demonstrating for the first time 
histamine-induced activation of phospholipase C (Subramanian et al., 1981). Currently, H1 receptor-
induced phosphoinositide responses mediated by Gq/11 activation have been described in a variety 
of central and peripheral tissues and in isolated cell systems as well (Smit et al., 1999). 
 
The observation that histamine-evoked gastric acid secretion could not be blocked with classical 
antihistamines (H1 antagonists), led to the conclusion that other histamine receptors were involved. 
The receptor involved in mediating histamine-dependent gastric acid secretion was subsequently 
termed histamine H2 receptor (Black et al., 1972). It is generally accepted that H2 receptor is 
coupled to adenylyl cyclase through Gs.  However, it has been reported that the H2 receptor can 
also activate phospholipase C (Davio et al., 1995; Davio et al., 2002) and perhaps both pathways 
simultaneously (Delvalle et al., 1992; Wellner-Kienitz et al., 2003). In fact, the activation of signal 
transduction pathways is highly dependent on the cellular system under study and outcome of H2 
receptor activation is probably mediated by various intracellular mediators. 
 
A third histamine receptor, H3, was originally postulated in 1983 as a putative histamine 
autoreceptor responsible for controlling histamine release in rat cerebral cortical slices (Arrang et 
al., 1988). Since then, the H3 receptor has been shown to be coupled to modulation of adenylyl 
cyclase activity via Gi/0 activation, and has been associated to inhibition of neurotransmission in 
central (Clapham and Kilpatrick, 1992; Schlicker et al., 1993; van der Werf and Timmerman, 1989) 
and peripheral tissues (Burgaud and Oudart, 1993; Imamura et al., 1995; Ishikawa and Sperelakis, 
1987). 
 
More recently, a fourth histamine receptor has been described. The H4 receptor is also a GPCR and 
it is coupled to Gi/0, resulting in modulation of various signal transduction pathways (Oda et al., 
2000). The H4 receptor is prominently expressed in medullary and peripheral hematopoietic cells, 
namely eosinophils, neutrophils and CD4+ T cells (Zhu et al., 2001). The H4 receptor is involved in 
histamine-induced increases in intracellular calcium in human eosinophils (Raible et al., 1994), 
facilitating terminal myeloblast and promonocyte differentiation (Nakaya and Tasaka, 1988).  
 
Until now, the most clinically relevant uses of histamine receptor ligands are achieved through the 
regulation of H1 or H2 receptors, which are widely expressed in most tissues (Bakker et al., 2002). 
In this regard, H1 antihistamines are used in the treatment of several allergic conditions, such as 
rhinoconjunctivitis, urticaria, and atopic dermatitis. Traditionally, the efficacy of H1 antihistamines 
in allergic disorders was attributed primarily to inhibition of H1 receptors in endothelial cells of the 
postcapillary venules, resulting in decreased vascular permeability, exudation of fluid, protein and 
cells and increased peripheral resistance (Leurs et al., 2002). Nevertheless, H1 antagonists also 
inhibit the effect of histamine at H1 receptors in the airway smooth muscle and on afferent C fibers, 
causing bronchodilation and decreased mucosal and cutaneous itch, respectively. 
 
H2 antagonists have proved to be very active agents for the treatment of duodenal and gastric ulcers, 
reflux, esophagitis and the Zollinger-Ellison syndrome. Since H2 receptors are abundant throughout 
the body, it is rather remarkable that H2 antagonists have not found other applications. Several 
studies have claimed beneficial effects of H2 antagonists in, e.g. viral diseases and alleviation of 
psoriasis (Nielsen, 1991), with no conclusive results. 
 
The identification of H3 and H4 receptors and their pattern of expression has lead to a renewed 
interest in the potential homeostatic role of histamine in the brain ,, besides their established 
pleiotropic regulatory functions in the periphery. Although no central nervous system disease has 
been associated directly to histamine dysfunction until now, the H3 receptor is recognized as a drug 
target for neuropathic pain, sleep-wake disorders, including narcolepsy, and cognitive impairment 
associated with attention deficit hyperactivity disorder, schizophrenia, Alzheimer’s, or Parkinson’s 
disease and the first specific H3 receptor ligands have already entered phase I–III clinical trials 
(Tiligada et al., 2011). However, before their introduction in the market, H3R ligands may require 
further testing to identify the determinants of their clinical efficacy. 
 
Nowadays, more than forty H1 antihistamines are therapeutically available worldwide. However, 
some of them, such as astemizole and terfenadine, have been associated with cardiac toxic effects 
and are no longer approved for use in most countries (Yap and Camm, 2002). On the other hand, H2 
antagonists, widely used as antiacids, were overcome by proton-pump inhibitors, due to their more 
favorable efficacy and safety profiles. However, a recent survey revealed that between the twenty 
most commonly used prescription and over-the-counter drugs are antiallergic formulations acting at 
H1 (difenhydramine and loratadine), and antiacids acting at H2 receptors (ranitidine) (Kaufman et 
al., 2002). 
 
From the mechanistical point of view, it has been proven in vitro that clinically relevant histamine 
receptor ligands do not act as simple antagonists, but rather as inverse agonists stabilizing inactive 
forms of the H1 and H2 receptors (Leurs et al., 2002; Smit et al., 1998). These observations have 
lead to the pharmacological reclassification of histamine H1 and H2 specific antagonists. The 
concept of inverse agonism arose from experimental observations showing that certain drugs were 
able to reduce the activity of receptor systems that were active in the absence of agonists. The 
inverse agonists  possess, in consequence, negative efficacy. According to existing receptor 
occupancy models, there are several mechanisms whereby inverse agonists exert their negative 
efficacy, and each one may lead to distinct consequences. However, whether inverse agonism is 
essential or important for these drugs to exert their medicinal actions has not been clarified yet. This 
point deserves attention due to the widespread use of histamine receptor ligands reclassified as 
inverse agonists in clinical treatments. In the following sections we will discuss these aspects of 
clinically used histamine receptor ligands in the context of their pharmacological safety.
2. Spontaneous receptor activity. The rise of the inverse agonism concept. 
 
Due to the recognition that many receptors are able to spontaneously activate downstream effector 
protein (reference) pharmacology experienced a rebirth in the understanding of the molecular 
mechanisms triggered by molecules that modulate receptor function. As a result, there was a 
significant realization of the importance of explicitly formulating spontaneous receptor activity 
observed both in natural and artificial systems (Costa and Cotecchia, 2005; Kenakin, 1995). This 
realization led to the formulation of the two-state model (TSM) (Leff, 1995; Robertson et al., 1994) 
and related reaction schemes developed later (Bindslev, 2004; Hall, 2000; Weiss et al., 1996a; Weiss 
et al., 1996b; Weiss et al., 1996c). 
 
Increasing numbers of compounds previously classified as antagonists were shown to inhibit this 
spontaneous or constitutive receptor activity (Kenakin, 2004). These thought-to-be antagonists with 
negative efficacy are now known as ‘inverse agonists’, whereas compounds that antagonize the 
inhibitory effect of agonists and inverse agonists without having an effect of their own are still 
termed antagonists, or more precisely neutral antagonists (Chidiac, 2002; Kenakin, 2004; Milligan 
et al., 1995; Strange, 2002). 
 
Classically, efficacy (whether positive, negative or zero) was thought as a separate property 
unrelated to affinity. However, in thermodynamic terms, this representation presents a paradox 
because the molecular forces that control affinity are the same as those controlling efficacy 
(Kenakin and Onaran, 2002). Taking this into account, it is not surprising that 85% of the ligands 
formerly known as antagonists have been shown to posses negative efficacy (Kenakin, 2004). 
 
3. Theoretical models of ligand-receptor occupancy and the mechanisms of inverse agonism. 
Receptor activity measured in functional studies can be either basal (i.e.spontaneous, constitutive 
and ligand-independent), or agonist-induced. This experimental observation is independent of the 
model used to interpret the system. However, different spontaneous receptor conformations can be 
hypothesized to be responsible for the basal activity, comprising a “receptor native ensemble”. 
Hence, as we are going to discuss in the next paragraph, the uniformity of the concept of 
constitutive receptor activity is apparently challenged when the spontaneous receptor species (and 
therefore the source of the receptor basal activity) are explicitly formulated (Kenakin, 2002; Onaran 
and Costa, 1997) (Fig. 1). 
 
For the TSM, receptors can spontaneously adopt only two forms, the resting or inactive state (R), 
and the active one (R*), to which the basal activity of the system is formally attributed. However, 
when accessory proteins (G-proteins) are included in the models, as in the extended ternary 
complex model (ETCM) (Samama et al., 1993), the native ensemble involves three distinct receptor 
forms including the inactive (R) and the active species (R*), but also an active G-protein coupled 
receptor form that is considered responsible for basal activity (R*G). 
Similarly, the cubic ternary complex model (CTCM) (Weiss et al., 1996a; Weiss et al., 1996b; Weiss 
et al., 1996c) adds one more receptor form to the native ensemble, allowing receptor to couple to G-
protein in an inactive form (RG).  
 
The CTCM was originally proposed in an attempt to explore the mathematical and pharmacological 
implications that can be derived from permitting G-proteins to interact with receptors in their 
inactive and active forms irrespectively. However, it is worth noting that regardless of its theoretical 
origins, there are empirical observations supporting the CTCM. Some mutants of 1B-adrenergic 
receptors are able to spontaneously couple to G-protein inactivating it (Chen et al., 2000), and this 
has also been observed for non-mutant serotonin 5HT7 and histamine H2 receptors (Andressen et al., 
2006; Tubio et al., 2010). 
 
The three models and their relations are schematically shown in Fig. 2. The fact that these models 
assume differences in the receptor states that exist spontaneously, implies these models could be 
used to explain ligand-dependent selection and stabilization of different preexisting receptor 
conformations. According to the law of mass action, when a factor affects previously established 
equilibriums, the receptor species are redistributed to re-establish equilibrium. Consequently, for all 
the models, inverse agonists exert their effect favoring the inactive receptor species at the expense 
of the active ones. However, the particular receptor species favored changes depending on the 
model. In this way, according to the TSM, inverse agonists suppress the spontaneous activity of the 
receptors by stabilizing them in an inactive state. Similarly, in the ETC model, inverse agonists may 
act by preferentially binding to the R state over the R* state (<1). In both cases, R*G species will 
be depleted as more receptor transforms into ligand-bound inactive R (LR), resulting in a decreased 
constitutive activity. There are several experiments that confirm this model, at least for the 2- and 
2-adrenergic receptors (Samama et al., 1993; Wade et al., 2001).Additionally, for the ETCM, 
ligands could bind to uncoupled states of the receptor (R and R*) in preference to the coupled state 
(R*G) (<1). This feature was described for 5-HT1A and 5-HT2C receptors, cardiac muscarinic 
receptors (M2 receptors), and dopamine D2 receptors (De Lean et al., 1982; Martin et al., 1984; 
McLoughlin and Strange, 2000; Westphal and Sanders-Bush, 1994). 
 
Another possibility, only accounted for in the CTCM, is that inverse agonists bias the receptor to a 
G-protein coupled but inactive conformation of the receptor (RG). It is worth noting that in the ETC 
model a ligand with high affinity for receptor species coupled to G-proteins would necessarily elicit 
a response. In contrast, the CTC model allows a ligand with high affinity for a receptor species 
coupled to G-protein to behave as an inverse agonist. 
 
For the ETC model a ligand that facilitates receptor activation (>1), promotes that the active 
receptor has more affinity for G-protein than the inactive form (>1), and improves G-protein 
coupling (>1), is defined as an agonist. However, a negative cooperativism among those receptor 
modifications may exist in the sense that ligands might behave as inverse agonists. This point is a 
distinctive feature of the CTC model and is made possible by proposing the  parameter, which 
represents the synergism among the receptor modifications (activation, binding to ligand, or 
coupling to G-protein). Therefore in the conceptual frame of the CTC it can be theoretically 
predicted, and then empirically proved, that an inverse agonist can exert its effect by stabilizing a 
G-protein coupled but inactive form of the receptor. Consequently, it can be inferred that if the G-
protein is in limiting quantities, the ligand will be able to interfere with the signaling of other 
unrelated GPCRs that share the same signaling cascade. This effect can be interpreted in terms of a 
G-protein “molecular kidnapping“, mediated by the inverse agonist-bound receptor (Fig. 3). This 
theory explains some experimental observations made not only for ligands acting at H1 and H2 
histamine receptors (Fitzsimons et al., 2004; Monczor et al., 2003), but also for ligands acting at -
opioid and CB1 cannabinoid receptors, that interfere with the signaling of other related receptors 
(Bouaboula et al., 1997; Brown and Pasternak, 1998). This view can also take account of some 
striking results obtained for D2 dopamine and M3 muscarinic receptor ligands, showing that an 
inverse agonist can exert its effects without promoting the expected receptor G-protein uncoupling 
(Dowling et al., 2006; Wilson et al., 2001). 
 
This interference of an inverse agonist of a given GPCR on the signaling of a non related receptor 
highlights the importance of the study of the mechanistic basis of action of ligands with negative 
efficacy. Taking into account that this may be a generalized feature of several ligands with clinical 
uses, a deeper understanding of this phenomenon could help to rationalize otherwise unexpected 
drug effects. Regarding this, the current as well as potential uses of inverse agonists of the 
histaminergic receptors in clinical treatment are discussed in the next section. 
 
4. Potential clinical uses of inverse agonists of the histaminergic receptors. 
When inverse agonism was first described, there were concerns on whether it was of therapeutic 
relevance in vivo or just a curious observation induced by laboratory conditions (Milligan et al., 
1995). Since then, hundreds of well-known drugs of extensive clinical use have been tested and 
reclassified for this property. However, questions on the therapeutic relevance of inverse agonism 
remain. 
Prominent examples of extensively used drugs formerly reclassified as antagonists and currently 
reclassified as inverse agonist due to their negative efficacy in vitro include: propranolol, 
alprenolol, pindolol, and timolol used for treating hypertension, angina pectoris, and arrhythmia 
acting on the 2-AR; metoprolol and bisoprolol used for treating hypertension, coronary heart 
disease, and arrhythmias acting on 1-AR; cetirizine and loratadine for treating allergies and hay 
fever acting on histamine H1 receptor; cimetidine and ranitidine used to treat heartburn and peptic 
ulcer acting on the histamine H2 receptor; prazosin and phentolamine for treating hypertension 
acting on 1-adrenergic receptors; atropine used as premedication for anesthesia and pirenzepine 
used for treatment of peptic ulcer acting on the muscarinic receptors and naloxone used for treating 
heroin overdose acting on -opioid receptor (Kenakin, 2004). 
 
At a first glance, it may seem there is no theoretical or practical reasons to believe that inverse 
agonists should have an intrinsic benefit over an antagonist in many situations where drugs are 
clinically used. In general, drugs are simply used to regulate the release of an endogenous agonist or 
to compete with it and limit its actions. Therefore potency, bioavailability and selectivity seem the 
key issues to consider. However, in a range of circumstances, specific benefits of using an inverse 
agonist can be envisaged.  
 
A first requirement to conceive an advantage in using an inverse agonist over an antagonist is that 
the receptor displays constitutive activity in vivo. In this sense, the constitutive activity of GPCRs in 
native in vivo systems has been proved only for few receptors, specifically including H2 and H3 
histamine receptors, acting at CNS. The H2 receptor was shown to display spontaneous activity in 
the sustancia nigra region and this activity regulated serotonin independently of the local histamine 
tone. This observation has implications not only for Parkinson's disease, where histamine levels in 
the sustancia nigra are increased, but also for other neuropsychiatric disorders in which serotonin is 
pivotal (Threlfell et al., 2008). In turn, constitutive activity of native H3 receptors was shown in 
rodent brain controlling histamine-dependent neuronal activity in vivo. The activation of 
histaminergic neurons, which promotes arousal and attention and improves learning in normal 
animals, has been proposed as a symptomatic therapeutic approach in human attentional and ageing 
disorders, and such an effect is more likely to be obtained with H3 receptor inverse agonists rather 
than with neutral antagonists (Morisset et al., 2000). 
 
On the other hand, there are clinical instances where the pathological entity is a constitutively active 
GPCR, which produces physiological response in the absence of endogenous agonists. In these 
circumstances, the underlying condition may be only effectively treated with inverse agonists. 
Mutations, which may be preserved in the germ line, have been shown to occur in GPCRs and 
result in constitutive receptor activity in patients with clinical syndromes, such as Jansen's 
metaphyseal condrodysplasia or congenital hyperthtyroidism (Bastepe et al., 2004; Davies et al., 
2005; Seifert and Wenzel-Seifert, 2002). Most of these diseases are associated with the endocrine 
system, although visual alterations due to rhodopsin mutations (Dryja et al., 1993; Keen et al., 
1991) and some viral infections were also related to constitutively active forms of GPCRs 
(Arvanitakis et al., 1997; Fitzsimons et al., 2006; Maussang et al., 2009). 
 
There are also many examples where inverse agonists may be useful for cancer treatment. For 
instance, high levels of specific GPCR expression have been described in tumour cells, where it has 
been shown that their endogenous ligands, present at high levels in the tumour cells (el Battari et al., 
1988; Gespach et al., 1988; Korman et al., 1986; Virgolini et al., 1994), enhance cell proliferation 
(Kroog et al., 1995; Pincus et al., 1990; Zurier et al., 1988). The histamine H2 receptor represents 
one interesting example of this property (Davio et al., 1995; Fitzsimons et al., 1999; Molnar et al., 
2001). Interestingly, some early studies made in rats bearing experimental mammary 
adenocarcinomas showed that anti H2 ligand administration resulted in the remission of a significant 
number of tumours, while also increased the survival of treated animals (Cricco et al., 1993; Rivera 
et al., 1993). Moreover, diverse clinical reports suggest that H2 antagonists/inverse agonists have 
potential beneficial effects in the treatment of advanced malignant diseases such as colorectal 
cancer, gastric cancer, liver metastasis, multiple myeloma, chronic lymphocytic leukaemia and 
melanoma (Burtin et al., 1988; Nielsen, 1996; Nielsen and Kikuchi, 1993). In those cases, inverse 
agonists would block not only the effects of humoral activation in cancer cells (i.e. secreted 
histamine) but also increased basal activity of these receptors in the tumour due to receptor 
overexpression. 
 
The studies summarized above provide supporting evidences for the relevance of pathological 
constitutive activity, suggesting the potential therapeutic values of its modulation. However, these 
potential advantages need to be tested for correlation with clinically relevant beneficial or 
detrimental effects. For this reason, and two decades after the discovery of inverse agonism on 
GPCRs, we have just begun exploring evidence of the clinical relevance of inverse agonists. 
However, it is worth noting that none of the above described diseases that involve pathological 
consequences of a constitutively active GPCR are in fact treated with inverse agonists. As suggested 
by Kenakin, translational research of inverse agonism will show whether new therapeutic options 
will emerge (Kenakin, 2004), especially for silencing the constitutively active mutant receptors that 
cause the diseases described above. 
 
Up to this point, we have described only examples of desirable acute effects of inverse agonists. 
Alternatively, inverse agonists may require chronic administration and therefore exert some 
undesirable effects. For instance, receptor up-regulation could occur as it was observed for the H2 
receptor after long-term treatment with cimetidine or ranitidine (Osawa et al., 2005; Smit et al., 
1996), providing a plausible explanation for the tolerance to these inverse agonists after prolonged 
clinical use. In the same way, Milligan and colleagues showed that inverse agonists also up-regulate 
2- and 1B-ARs (Georgieva et al., 2008; Lee et al., 1997; MacEwan and Milligan, 1996). 
 
Recently, it has been shown that the CB1 receptor inverse agonist rimonabant suppresses receptor 
constitutive activity in the ventral tegmental area and basolateral amygdala, reducing weight gain 
and food intake, but also causing anxiety and reduced motivation for reward, while NESS0327, 
acting as a neutral antagonist on the same receptor, is equally effective on reducing weight gain and 
food intake, but lacks the negative effects associated with rimonabant’s inverse agonism. 
Considering that rimonabant has been discontinued for human treatment because its use was 
occasionally associated with negative effects and suicidality, the findings suggest that neutral CB1 
receptor antagonists can treat obesity more efficiently and safely than inverse agonists (Meye et al., 
2012).  
 
In conclusion, in this review we not only emphasize the importance of proper classification of 
ligands of constitutively active receptors, but also the importance of elucidating the molecular 
mechanisms by which these ligands exert their actions in terms of their clinical applications and 
pharmacological effects. An inverse agonist may act by three different ways: biasing the system to 
an inactive form of the receptor; facilitating the G-protein uncoupled forms; or promoting a G-
protein coupled but inactive form of the receptor. If the preferred mechanism for a given ligand 
would be the third one, it may not only diminish the activity of the specific receptor but it may also 
interfere with the signalling of other non-related GPCRs. This is the case for some cannabinoid CB1 
(Bouaboula et al., 1997; Georgieva et al., 2008),  opioid (Brown and Pasternak, 1998) and 
dopamine D2 receptor (Wilson et al., 2001) ligands and, of central interest for this review, also for 
H1 and H2 ligands (Fitzsimons et al., 2004; Monczor et al., 2003).  
 
This interference with the signaling of other GPCRs, may bring some unexpected effects that would 
not be observed with inverse agonists that do not promote G-protein sequestration, and could 
rationalize the appearance of pharmacological interactions and/or side effects that would be 
otherwise difficult to explain. 
 
Ligands acting at histaminergic system are among the most widely prescribed and over-the-counter-
sold drugs in the world, and there is a trend to use them as long-term therapeutics rather than 
restricting them to the treatment of short-term manifestations. Within this context, progress in the 
understanding of their mechanism of action is of crucial importance to improve their safety and 
specificity. Taking into account the clinically widespread use of histamine antagonists acting at H1 
and H2 receptors in the treatment of several human diseases, the proper pharmacological 
classification of these ligands and the accurate characterization of their mechanism(s) of action is of 
great importance. 




The figure shows the theoretical receptor species available for ligand binding. Inactive receptor 
conformations are presented on the left and the active ones on the right of the equilibrium arrows. 
Depending on the specific ligand-receptor interactions the ligand can redistribute the spontaneous 
receptor conformations, thereby favoring or disfavoring basal activity. This action of the ligand 
results from binding preferentially inactive or active species, or both, depending on whether the 
drug is an agonist, an inverse agonist, or eventually behaves as a neutral antagonist not affecting the 




The figure shows the three most common models used to describe GPCR behaviors. The models 
describe inactive receptor species (R) in spontaneous equilibrium with an active state (R*) 
responsible for the basal activity of the system. In the extended ternary complex model (center), 
activation of the receptor could be followed by binding of R* to the G-protein (G). The cubic 
ternary complex model (right) implies the same asumption, but also allows the ligand-bound or 
unbound inactive-state receptor species (LR or R) to form a non-signaling complex with the G-
protein (LRG or RG, respectively). Dotted arrows point to species that could be favored by inverse 
agonists, diminishing receptor basal activity. It should be noted that there is a trend in the 
complexity where following scheme contains the previous, and that the liganded inactive receptor 
species are different for each model, implying different mechanisms of action accounting for 
inverse agonism. These different mechanisms are discussed in the main text.
Figure 3.  
 
The figure represents how an inverse agonist, acting on a specific receptor species and promoting 
the coupling to the G-protein to a receptor inactive state (LRG complex, see figure 2) can interfere 
with the signaling of a second unrelated receptor that transduces its signal through the same G-
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